| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In the presence or absence of 10% serum, MF498 (0.01 nM–10 μM, 30 minutes) suppresses PGE2-stimulated cAMP buildup with IC50 values of 1.7 and 17 nM, respectively [1]. In VSMC, MF498 0.01 and 0.1 μM, 30 minutes) suppresses the proliferation of VSMC produced by FBS and PDGF-BB [2]. In VSMC, MF498 (0.1 μM, 30 minutes) suppresses the expression of PCNA and cyclin D1 produced by PDGF [2]. The PDGF-BB-induced migration is inhibited by MF498 (0.1 μM, 30 min) [2].
|
|---|---|
| ln Vivo |
The Wall Street compound MF498 (0–20 mg/kg) reduces foot swelling in adjuvant-induced arthritis (AIA) [1]. In guinea pigs (L-902688), MF498 (0-30 mg/kg, Wall Street) attenuates EP4 vessels. At a dosage of 1.2 μM, six hours after the laboratory, MF498 (20 mg/kg, buccal) exhibits 100% bioavailability [1].
|
| Cell Assay |
Cell viability assay [2]
Cell Types: Rat VSMC Tested Concentrations: 0.01 nM-10 μM Incubation Duration: 30 minutes before FBS treatment. Experimental Results: Inhibited VSMC proliferation induced by FBS and PDGF-BB. |
| Animal Protocol |
Animal/Disease Models: Adjuvant-Induced Arthritis (AIA) in Rats[1]
Doses: 0, 0.008, 0.04, 0.2, 2, 20 mg/kg Route of Administration: Oral (po) Experimental Results: In primary and secondary paws All demonstrated anti-inflammatory effects. |
| References |
|
| Molecular Formula |
C32H33N3O7S
|
|---|---|
| Molecular Weight |
603.69
|
| Exact Mass |
603.203
|
| CAS # |
915191-42-3
|
| PubChem CID |
15948325
|
| Appearance |
Pink to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.630
|
| LogP |
4.64
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
43
|
| Complexity |
1070
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WVLIUERFVJYBNY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H33N3O7S/c1-5-41-30-23-11-9-15-33-29(23)31(42-6-2)24-18-35(32(37)28(24)30)25-14-13-21(16-20(25)3)19-43(38,39)34-27(36)17-22-10-7-8-12-26(22)40-4/h7-16H,5-6,17-19H2,1-4H3,(H,34,36)
|
| Chemical Name |
N-[[4-(5,9-diethoxy-6-oxo-8H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylphenyl]methylsulfonyl]-2-(2-methoxyphenyl)acetamide
|
| Synonyms |
MF-498; MF 498; MF498
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 31 mg/mL (~51.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6565 mL | 8.2824 mL | 16.5648 mL | |
| 5 mM | 0.3313 mL | 1.6565 mL | 3.3130 mL | |
| 10 mM | 0.1656 mL | 0.8282 mL | 1.6565 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
